Targeting T-cell Signals for Adult T-cell Leukemia Lymphoma
Official title: Inhibition of T-cell Receptor Signaling for Treatment of Adult T-cell Leukemia Lymphoma
Funded at Washington University · NIH-11129773 · Data updated 2026-11-12
This project explores new ways to treat adult T-cell leukemia lymphoma by blocking specific signals within cancer cells.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project start | August 15, 2022 |
| Project end | June 30, 2027 |
| Funding year | 2025 |
| Award (this year) | $360,282 |
| NIH project number | 5R01CA258359-04 |
| Project ID | NIH-11129773 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with HTLV-1-associated adult T-cell leukemia lymphoma, particularly those who might be eligible for a Phase 1 clinical trial combining lenalidomide with EPOCH chemotherapy, would be ideal candidates.
✕Less likely to help
Patients without adult T-cell leukemia lymphoma or those whose cancer does not involve the specific T-cell receptor signaling pathway mutations being targeted may not receive direct benefit from this particular approach.
What this research studies
Adult T-cell leukemia lymphoma (ATLL) is a very serious blood cancer that is often hard to treat with current methods. Researchers have found that ATLL cells often have changes in a specific communication pathway, called the T-cell receptor (TCR) signaling pathway, which helps the cancer grow. This work aims to understand how these changes drive ATLL and if medicines that target this pathway, like lenalidomide, can work better when combined with standard chemotherapy. The goal is to find more effective treatments for this aggressive disease.
Why it matters
Potential benefit: If successful, this approach could lead to new, more effective treatment options for patients with adult T-cell leukemia lymphoma, potentially improving outcomes where current therapies often fail.
How similar studies have gone: While the specific combination and targeting of this pathway in ATLL is being explored, the concept of targeting specific signaling pathways in cancer has shown success in other types of leukemia and lymphoma.
Where this research is happening
-
Washington University
Saint Louis, United States Active
Researchers
- Principal investigator: Ratner, Lee — Washington University
- Study coordinator: Ratner, Lee
Related research
Other NIH-funded projects on the same topics.
-
Bone marrow grafting and cellular therapies for leukemia and lymphoma
A program at Stanford aims to improve bone marrow transplantation and newer cellular therapies to treat blood cancers like leukemia and lymphoma.
-
Inhibiting T-cell Signaling to Treat Adult ATLL
A study to test whether blocking T-cell receptor signaling can help treat adult T-cell leukemia/lymphoma caused by HTLV-1, potentially improving outcomes for patients.
-
Understanding EP300 deficiency in ATLL in adults
This grant explores how loss of EP300 affects an aggressive adult T-cell cancer (ATLL) to identify new ways to help patients.
-
3D gene switches in leukemia and lymphoma
Researchers will map and try to block 3D gene-control hubs that help T-cell leukemia and lymphoma cells grow, aiming to find new ways to help people with these cancers.
-
Improving bone marrow transplants and cell therapies for leukemia and lymphoma
New cell-based treatments and transplant methods aim to make bone marrow transplants safer and help people with leukemia or lymphoma avoid relapse.
-
Understanding the causes of Adult T-cell leukemia/lymphoma
This study is looking at Adult T-cell leukemia/lymphoma, a tough cancer that often hits young adults, especially veterans, to find out why some patients don’t respond well to treatment and how we can make those treatments better.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.